Kenneth Galbraith

Kenneth Galbraith is the CEO of Zymeworks Inc., a Vancouver-based biotechnology company specializing in cancer treatments. He took the helm following the departure of co-founder Ali Tehrani and has been instrumental in steering the company towards success, particularly with the lead drug Ziihera, which has shown promising results in clinical trials for digestive system cancers. Under his leadership, Zymeworks has secured a partnership with Jazz Pharmaceuticals to commercialize Ziihera, significantly improving investor confidence and the company’s stock performance.